HGERS
CRSP icon

Householder Group Estate & Retirement Specialist’s CRISPR Therapeutics CRSP Stock Holding History

Householder Group Estate & Retirement Specialist’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$2K – 669
2024
Q3 		$2K Hold
50
– – ﹤0.01% 1026
2024
Q2 		$2K Hold
50
– – ﹤0.01% 1055
2024
Q1 		$3.41K Hold
50
– – ﹤0.01% 984
2023
Q4 		$3K Hold
50
– – ﹤0.01% 938
2023
Q3 		$2.27K Buy
+50
New +$2.58K ﹤0.01% 1049
2023
Q1 		$2K Sell
50
-205
-80% -$9.96K ﹤0.01% 1069
2022
Q4 		$10K Buy
255
+10
+4% +$530 0.01% 227
2022
Q3 		$16K Buy
+245
New +$17.8K 0.01% 624

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Householder Group Estate & Retirement Specialist's CRSP Position: Q4 2024 in Review

Householder Group Estate & Retirement Specialist sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 50 shares — an estimated $2K sold.

Householder Group Estate & Retirement Specialist first reported a position in CRSP in Q3 2022 and held it in 8 quarters. The position peaked at $16K in Q3 2022. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Householder Group Estate & Retirement Specialist reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Householder Group Estate & Retirement Specialist sold 50 CRISPR Therapeutics shares in Q4 2024, an estimated $2K.
  • Householder Group Estate & Retirement Specialist first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 8 quarters.
  • Householder Group Estate & Retirement Specialist's CRISPR Therapeutics position peaked at $16K in Q3 2022.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Householder Group Estate & Retirement Specialist's 13F filing for Q4 2024, filed 15 Jan 2025.